Quest Diagnostics Incorporated (DGX) Fair Value 2026

DGX · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.9 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-27, Quest Diagnostics Incorporated (DGX) trades at $244.61, versus a $225.49 median fair value across its 11 active models — 7.8% below the current price. QOC: 7.9/10. Value Trap Risk: 19/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $249.40.

Key Facts

Ticker
DGX
Price
$244.61
Quality Score
7.9/10
Value Trap Risk
19/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +85.7% upside with 61% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Quest Diagnostics Incorporated (DGX) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Quest Diagnostics Incorporated (DGX) appears fairly valued as of : the median of 11 independent fair value estimates is $225.49, within 7.8% of the current price of $244.61. Estimates range from $73.61 to $454.36. DGX scores 7.9/10 on fundamental quality and 19/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. DGX’s -7.8% gap is narrower than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Quest Diagnostics Incorporated Stock in 2026? →

What Fair Value Does Each Model Give DGX?

11 Intrinsic Value Models vs. Current Price ($244.61)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $249.40 +2.0%
Intrinsic · High Conviction
 $137.64 -43.7%
Ensemble · Medium Conviction
 $225.49 -7.8%
Scenario · High Conviction
 $454.36 +85.7%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is DGX's Fair Value Range?

Spread across 11 independent models · $73.61 to $454.36

CirclFi's 11 active models place Quest Diagnostics Incorporated (DGX) between $73.61 and $454.36 per share, a spread of 169% of the median. The median of that range — $225.49 — is the fair value CirclFi publishes for DGX, against a current price of $244.61.

Low · EROICHigh · First Chicago
$73.61median $225.49$454.36
Where the range comes from
Most bearish modelEROIC Spread$73.61
Most bullish modelFirst Chicago$454.36
Model agreement4 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for DGX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on DGX, not a CirclFi price target. How each model works →

What Is Quest Diagnostics Incorporated (DGX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Quest Diagnostics Incorporated presents a highly debated valuation profile at its current price of $244.61. The median intrinsic value is estimated at $225.49 (-7.8% median upside), masking a wide model spread between the 4 bullish models and 6 bearish models. Model dispersion is worth noting: First Chicago targets $454.36 (+85.7%), versus EROIC at $73.61 (-69.9%). This +155.7% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About DGX?

11 of 13 models are currently active for DGX. Of these, 5 models suggest upside while 6 models suggest overvaluation. Taken together, their median fair value for DGX is $225.49 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $249.40 on its own, implying +2.0% upside from the current price. See which stocks rank higher →

How Does DGX Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, DGX ranks #11 by Quality of Company score. CirclFi's QOC score of 7.9/10 evaluates 32 fundamental signals. A score of 7.9 indicates above-average quality.

As a biopharma enterprise, Quest Diagnostics Incorporated operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating DGX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is DGX a Value Trap?

CirclFi's Value Trap algorithm assigns DGX a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Quest Diagnostics Incorporated. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Quest Diagnostics Incorporated is rated at 7.9/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

The gap between the most bullish and bearish model spans +155.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DGX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across DGX's 11 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Quest Diagnostics Incorporated Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

SHCSotera Health CompanyQOC 8.1TMOThermo Fisher Scientific Inc.QOC 7.8DHRDanaher CorporationQOC 8.1BLLNBillionToOne, Inc.QOC 7.7IDXGInterpace Biosciences, Inc.QOC 8.2WATWaters CorporationQOC 7.7FLGTFulgent Genetics, Inc.QOC 7.0IMDXInsight Molecular Diagnostics Inc.QOC 6.1ICLRICON Public Limited CompanyQOC 2.8IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: SHC · TMO · DHR · BLLN · IDXG · WAT · FLGT · IMDX · ICLR · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to DGX?

7 companies across all industries closest to DGX’s Quality of Company score of 7.9/10.

KFRCKforce Inc.QOC 7.9PXSPyxis Tankers Inc.QOC 7.9GLPIGaming and Leisure Properties, Inc.QOC 7.9CIThe Cigna GroupQOC 7.9SODISolitron Devices, Inc.QOC 7.9LEATLeatt CorporationQOC 7.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KFRC · PXS · GLPI · CI · SODI · LEAT · NVDA

What Else Do Investors Ask About Quest Diagnostics Incorporated’s Valuation?

What is Quest Diagnostics Incorporated's intrinsic value in 2026?

CirclFi puts Quest Diagnostics Incorporated (DGX)'s intrinsic value at $225.49 — the median of 11 independent model estimates as of 2026-08-27, ranging from $73.61 to $454.36. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $249.40 on its own. The Quality of Company score is 7.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DGX overvalued or undervalued right now?

At $244.61, 5 of 11 active models suggest DGX may be undervalued, while 6 indicate potential overvaluation. The median of all 11 fair value estimates is $225.49, within 7.8% of the current price of $244.61 — a consensus view that DGX is fairly valued. The assessment depends on which methodology best fits Quest Diagnostics Incorporated's business model in Diagnostics & Research.

What does a Quality of Company score of 7.9 mean for DGX?

Quest Diagnostics Incorporated's QOC of 7.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on DGX?

CirclFi analyzes DGX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on DGX?

Of the 11 models currently active on DGX, First Chicago is the most bullish at $454.36 per share, and EROIC Spread is the most bearish at $73.61. CirclFi's published fair value for DGX is the median of that range, $225.49, not either extreme. The gap between the two ends equals 169% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is DGX a value trap in 2026?

Quest Diagnostics Incorporated's Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Quest Diagnostics Incorporated (DGX) has a median fair value of $225.49 — within 7.8% of the current price of $244.61 — as of 2026-08-27.” Source: circlfi.com/stock/DGX/ · Methodology
Primary sources for this DGX valuation
  • Financial statements: Quest Diagnostics Incorporated 10-K and 10-Q filings on SEC EDGAR (CIK 0001022079) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for DGX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on DGX.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for DGX Unlock All 11 — $39/mo